Journal of Clinical Oncology 2012

21 papers
In 2012, the Journal of Clinical Oncology emphasized research directions such as aligning clinical studies with patient-reported outcomes and closing the evidence-practice gap. A recurring theme involved quantifying medical value through incremental cost-effectiveness analysis. Clinical research focused heavily on molecular markers and targeted therapies across various malignancies. For instance, studies examined gene modules in breast cancer subtypes and the prognostic role of KRAS mutations in metastatic colorectal cancer. Other work included the evaluation of dose-escalated radiation therapy for prostate cancer and the development of Tc-99m labeled small-molecule inhibitors for imaging metastatic disease. Research in lung adenocarcinoma explored the efficacy of erlotinib and the correlation of ERCC1 expression in circulating tumor cells with patient survival. Prolific contributors during this period included Everett E. Vokes, Martin J. Edelman, and Leslie L. Robison. Methodological papers also assessed the safety of research-related tumor biopsies in trials involving anti-angiogenic agents, reflecting a trend toward integrating molecular diagnostics and cost-utility metrics into clinical decision-making.

Top Authors

AuthorPapers
Jorge J. Nieva2
Xiaofei Wang2
Anobel Odisho1
Benjamin Haibe-Kains1
Bradford J Wood1
Christopher Lum1
Jared D. Acoba1
Jianhua Chen1
Søren Jensby Nielsen1
Thórarinn Blöndal1

Papers

Title
Analysis of KRAS and BRAF mutant colorectal cancers in a multiracial population.
Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Biomarker Evaluation From the AVAGAST Randomized Phase III Trial
Correlation of ERCC1 expression on circulating tumor cells with progression-free survival in metastatic non-small cell lung cancer patients treated with platinum-based chemotherapy.
Cyclooxygenase-2 (COX-2) As a Predictive Marker for the Use of COX-2 Inhibitors in Advanced Non–Small-Cell Lung Cancer
Designing a web application for personalized medicine trials.
Dietary intake and metabolic syndrome in adult survivors of childhood cancer.
Effect of adding short-term androgen deprivation therapy to dose-escalated radiation therapy on failure-free survival for select men with intermediate-risk prostate cancer.
Feasibility and safety of sequential research-related tumor core biopsies in clinical trials with anti-angiogenic and targeted therapies.
Final overall survival and updated biomarker analysis results from the randomized phase III ICOGEN trial.
Gene Modules and Response to Neoadjuvant Chemotherapy in Breast Cancer Subtypes: A Pooled Analysis
KRAS mutation as a prognostic factor in patients undergoing hepatic resection for metastatic colorectal cancer.
Outcomes for Radical Prostatectomy: Is It the Singer, the Song, or Both?
Performance of the high-definition circulating tumor cells (HD-CTC) assay in patients with non-small cell lung cancer (NSCLC).
Randomized phase II clinical trial to assess MUC1 specific immune response to L-BLP25 vaccine in addition to standard therapy in newly diagnosed high-risk prostate cancer.
Randomized Phase II Trial of Erlotinib Alone or With Carboplatin and Paclitaxel in Patients Who Were Never or Light Former Smokers With Advanced Lung Adenocarcinoma: CALGB 30406 Trial
Secondary Colorectal Carcinoma After Childhood Cancer
89 Zr-bevacizumab PET imaging in metastatic renal cell carcinoma patients before and during antiangiogenic treatment.
Tc-99m labeled small-molecule inhibitors of prostate-specific membrane antigen (PSMA): New molecular imaging probes to detect metastatic prostate adenocarcinoma (PC).
Trimodality therapy for stage II-III carcinoma of the esophagus: A dose-ranging study of concurrent capecitabine, docetaxel, and thoracic radiotherapy.
Use of colorectal cancer subtypes identified through iterative clustering to predict response to therapy.
Validation of a plasma-based miRNA PCR test for early detection of colorectal cancer.